BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Revalesio's RNS60 Protects Myelin and Halts Multiple Sclerosis in Mice


1/3/2013 9:54:42 AM

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ -- Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb paralysis), prevented inflammation in the brain and spinal column while also protecting against demyelination, a process that makes nerve cells lose their protective covering. The research demonstrated that administration of RNS60 - either at early disease onset or late at the relapsing phase - halted disease progression. Animals treated with RNS60 were protected from infiltration of inflammatory cells to the central nervous system, and thus had a significant preservation of the protective nerve covering (myelin). The full details of the study can be found in the journal PLOS ONE (Protection of Tregs, Suppression of Th1 and Th17 Cells, and Amelioration of Experimental Allergic Encephalomyelitis by a Physically-Modified Saline - December 20, 2012).

The study revealed further that RNS60 changed the over-reactive immune response associated with MS through increasing the population of regulatory T cells, which have protective function, while reducing the number of inflammatory Th17 T-cells. These results highlight a novel immunomodulatory role of RNS60 and suggest that this unique therapeutic may yield new treatment options for MS. Revalesio is preparing to test RNS60 in a Phase II MS clinical trial at Mt. Sinai Hospital in New York.

RNS60 is distinct from other therapeutic candidates in that it does not contain a chemical active component and instead is comprised of charge-stabilized nanostructures (CSN) in saline. The use of CSN-containing therapeutics represents a fundamentally novel approach to treating diseases. RNS60 has demonstrated significant anti-inflammatory and cellular protective activity across numerous diseases and is being investigated for clinical relevance in multiple human disease trials. RNS60 has been tested in two Phase I safety studies and has demonstrated an excellent safety profile with no known side effects.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines resulting in decreased inflammation and cell death. RNS60 contains CSN that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

About Multiple Sclerosis
Multiple sclerosis (MS) is a complex autoimmune disease that progressively shuts down the communication between the brain and the spinal cord, causing symptoms that range from limitations in the ability to speak, problems with vision, pain and tingling sensations, fatigue to complete limb paralysis and blindness. While numerous treatments for MS are available, none of them sufficiently addresses the patients' clinical needs, and many of them possess burdensome side effects. There is currently no cure for MS. Like other inflammatory diseases, MS involves the uncontrolled activity of immune cells. Lymphocytes and antibody-producing plasma cells infiltrate the brain and spinal cord and act in concert with resident immune cells to damage the insulating sheet around nerve cells built from a protein called myelin. Demyelination of neurons in MS ultimately leads to their inability to properly function and to their irreversible degeneration.

Press Contact:
Jesse Thomas
253-926-5567
contact@revalesio.com

This press release was issued through eReleasesĀ® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Revalesio Corporation



Read at BioSpace.com

Revalesio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES